Accelerate your therapeutic research with our high-quality afucosylated antibody expression service at evitria.
We provide afucosylated antibody expression services based on CHO cells. This enables us to express high-quality afucosylated antibodies for projects at different stages and scales – with no amino acid alterations.
Our expertise ensures that you receive afucosylated antibodies with enhanced Antibody-Dependent Cellular Cytotoxicity (ADCC), crucial for advancing therapeutic antibodies in immunotherapy and many other applications.
We can achieve this by accessing ProBioGen’s proprietary GlymaxX® system, ensuring the absence of fucose residues without the need for altering the amino acid sequence of your antibody.1
GlymaxX® antibodies purified for customers worldwide
4 weeks
from antibody sequence to delivery
Rapid Afucosylated antibody production service to support your development
There are many ways to enhance ADCC by Fc engineering (Table 1), but these require changing the amino acid sequence of your antibody – a big risk in any therapeutic development project.
Afucosylation, i.e. the removal of core fucose residues from antibody glycan structures is a way of enhancing ADCC without any amino acid substitutions. At evitria, we combine ProBioGen’s proprietary cell engineering approach, GlymaxX® with our transient CHO antibody expression platform to rapidly deliver high quality afucosylated antibodies.
By increasing ADCC through afucosylation, your antibody drugs can achieve greater efficacy against target cells. This is achieved by enhancing the interaction between the antibody’s Fc region and FcγrIIIa receptors on effector cells like natural killer cells (NK cells) or T-cells, leading to improved antibody-dependent cell-mediated cytotoxicity.2
Expression service for truly afucosylated antibodies? No matter of course!
ProBioGen’s GlymaxX® technology seamless integrates with our rapid transient CHO expression service. With these technologies, we can produce your ideal side-by-side comparison to study the impact of antibody afucosylation.
Simulataneously, we transfect one CHO cell culture with your recombinant monoclonal antibody, and another culture with your antibody plus the RDB enzyme of GlymaxX®. This enzyme redirects the fucose synthesis pathways within our CHO cells, and so prevents the addition of core fucose onto the Asn298 glycan structures within the antibody Fc domain. Both cultures grow, express the transfected antibody, and are purified in parallel using evitria’s robust plaform, delivering high quality material and the ideal wild-type control.
GlymaxX® avoids the risks associated with Fc mutations that could have an impact on immunogenicity, developability, and stability. By avoiding changes to the antibody’s oligosaccharide structures or N-linked glycosylation sites, we maintain the natural effector functions and stability of the antibody. We have verified this through mass spectrometry analysis, the gold standard of antibody characterisation, and can offer this enhanced analytics verification to any recombinant antibody production we perform.
We focus exclusively on recombinant antibody production service through transient expression in CHO cells. This means that all our strength and expertise go into the production of mAbs, bsAbs, and other antibody-related formats – including afucosylated antibodies, Fc-silenced antibodies, and other proteins. We also offer bispecific antibody expression services. Our dedicated team ensures rapid turnaround times and high-quality deliverables, so you can progress your research without delay.
Download our GlymaxX® technology spotlight to learn how the integrated GlymaxX® technology enhances ADCC activity without altering the amino acid sequence of your antibody.
Additionally, explore our PEGS poster to learn how an integrated workflow with advanced characterization validates ADCC-enhanced lead candidates.
Long-lasting, healthy customer relationships are very
important to us. Anonymity is therefore part of our corporate DNA.
“We have been working with evitria for several years and highly appreciate the high consistency of the delivered material.”
Sr. Scientist, Biotherapeutics, Switzerland
“We have been working with evitria since 2022. We appreciate the openness and flexibility of the team, the high speed and quality of the proteins they deliver.”
Radiopharm Theranostics Ltd.
“We are happy paying for the assured quality that evitria brings.”
Sr Scientist, Biotherapeutics, Series B Startup, Boston
Unsure on what afucosylated antibody you should use?
We’ve got you covered! Regardless of where your research is taking you, Lisa Meza is dedicated to supporting you on our afucosylated antibody expression service.
Our partnership with ProBioGen allows us to access the GlymaxX® platform – a cutting-edge technology for afucosylation. This system inhibits the enzymatic addition of fucose to the N-glycan structures on the Fc region of antibodies without any DNA sequence modifications. In other words: While alternative ADCC-enhancement approaches rely on Fc mutations that introduce risk of immunogenicity, developability, and stability risks, we can provide ADCC-enhanced materail without changing the sequence of your antibody.
By utilizing CHO host cells for our mammalian expression platform, we ensure high yields and scalability suitable for both small-scale assays and larger therapeutic antibody production. Our transient expression approach eliminates the need for stable cell line development, saving you time and resources.
With GlymaxX®, you receive antibodies with improved effector functions without compromising on quality or yield.
We know how tight timelines in biotechnological projects can be. With resources and know-how at hand, our efficient workflow allows us to provide you with recombinant antibodies within only 4 weeks. Starting with a pilot study, large-scale expression commences after 2 weeks, followed by purification, extensive analytics, and – finally – shipment of the deliverables to our customers worldwide.
Week 1
Week 2
Week 3
Week 4
Pilot Study*
Larger-scale expression
Purification
Final analytics
Shipment
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
Business days
High-Throughput Antibody Production Service
Accelerate early-stage antibody discovery with parallel CHO expression of up to several hundred constructs per project.
evitria’s HTP antibody production service delivers purified, assay-ready antibodies within 4 weeks – with the same Swiss-quality analytical package used at clinical scale. No host-cell transitions, no re-optimization, no delays.
Antibody-dependent cellular cytotoxicity is a key process of the immune system’s arsenal to ward off cancerous cells and infections. We show you important definitions and the ADCC mechanism and key facts on ADCC antibodies in this post.
Generally speaking, antibodies of any kind, including recombinant and afucosylated antibodies, are Y-shaped proteins produced by the human body. As they are able to identify and neutralize foreign objects – in other words viruses – they play a major contributing role in keeping our body and immune system healthy.
The importance of glycosylation patterns (sugar sequences) on proteins and their glycobiology have been intensely investigated in recent years, and the deeper understanding spawned novel applications that push biotechnology forward. vice offerings in the field of glyco-engineering.
Afucosylation stands as a critical phenomenon with far-reaching implications. This article aims to provide an exploration of afucosylation, shedding light on its significance and its role in various scientific fields.
Glycosylation is an essential biochemical process, which is also used in the production of recombinant proteins. In this article, we will explore it in more detail.
evitria expresses afucosylated antibodies using ProBioGen’s GlymaxX® platform, a cutting-edge technology that inhibits the addition of fucose to the N-glycan structures on the Fc region of antibodies. This process is done without any alteration of the antibody sequence, ensuring the antibodies retain their natural structure and functionality.
ProBioGen’s GlymaxX® platform offers several key benefits for the production of afucosylated antibodies:
This website uses cookies to enhance your browsing experience and provide personalized services. We require your consent to set these cookies on your device. Please note that we also use cookies from US companies that have not signed up to the EU-US data protection agreement.
Your Privacy
This site uses tracking technologies. You may opt in or opt out of the use of these technologies.
Marketing cookies and services are used to deliver personalized advertisements, promotions, and offers. These technologies enable targeted advertising and marketing campaigns by collecting information about users' interests, preferences, and online activities.
Analytics cookies and services are used for collecting statistical information about how visitors interact with website. These technologies provide insights into website usage, visitor behavior, and site performance to understand and improve the site and enhance user experience.
Personalization cookies enable the website to remember your choices and provide enhanced, more personal features. These cookies may track your preferences and show you relevant content based on your browsing patterns.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedback, and other third-party features.
Essential cookies are necessary for the website to function properly. These cookies ensure basic functionalities and security features of the website.
